Understanding Share Capital and Voting Rights
The latest information about share capital and voting rights is essential for shareholders and potential investors in understanding their stakes in Cellectis. This information enables them to gauge the company's performance and governance.
Cellectis Overview
Cellectis is a pioneering biotechnology company focused on gene editing technology. With a mission to develop immunotherapies that harness the power of the immune system, Cellectis has made significant strides in its field. As the landscape of biotechnology continues to expand and evolve, Cellectis stands out due to its innovative approaches and commitment to research.
Latest Share Capital Details
As of August 31, 2025, Cellectis reported a total of 100,325,229 shares in circulation, corresponding to a robust equity position. This number signifies an increase in available capital, which often indicates strong investor interest and potential growth opportunities.
Analysis of Voting Rights
Alongside the share count, the total voting rights available as of the same date were documented at 89,428,230. Voting rights are a crucial aspect of corporate governance as they affect control over company decisions. Stakeholders hold the power to influence matters such as board member elections and significant strategic initiatives.
Company Contacts for Further Engagement
For those interested in more detailed information, Cellectis has set up dedicated channels for investor and media inquiries. Pascalyne Wilson, the Director of Communications, is available for media-related questions at +33 (0)7 76 99 14 33. You can also reach out via email at media@cellectis.com.
Investor Relations
On the investor relations side, Arthur Stril serves as the Chief Financial Officer and Chief Business Officer. Prospective and current investors can contact him at investors@cellectis.com for investment-related inquiries. Engaging with the investor relations team can provide insights into the company’s strategy and financial performance.
Importance of Following Shareholder Updates
Staying abreast of share capital changes and voting rights is crucial for maintaining an informed investment strategy. These updates not only reflect the company's operational success but also highlight its commitment to transparency with stakeholders.
Final Thoughts
As Cellectis continues to innovate and expand within the biotechnology landscape, keeping informed of their share capital and voting rights will empower investors to make deliberate and informed decisions. The dynamic nature of this industry invites both opportunities and risks, which makes understanding this information all the more significant.
Frequently Asked Questions
What is Cellectis' main focus?
Cellectis specializes in gene editing technologies and developing immune-based therapies.
How many shares does Cellectis currently have?
Cellectis has reported a total of 100,325,229 shares as of August 31, 2025.
What are voting rights?
Voting rights allow shareholders to participate in decisions regarding the management and direction of the company.
Who can I contact for media inquiries at Cellectis?
For media inquiries, contact Pascalyne Wilson at +33 (0)7 76 99 14 33 or via email at media@cellectis.com.
What is the significance of shareholder updates?
Shareholder updates are crucial for understanding a company's performance and for making informed investment decisions.
